TN SB0491

The Death Penalty

Introduced Senate Janince Bowling (R)
Plain English Summary

AI summary is being generated. Check back soon for a plain-language breakdown of this bill.

Supporters Say

Positive media analysis is being generated.

Critics Say

Critical media analysis is being generated.

Conflict of Interest Analysis Personal Interests
1/10
Risk Level
Low
Policy Area
Crime and Law Enforcement
Industry Overlap
0%
Personal Conflicts
0 found

The bill SB0491, which pertains to the use of pharmaceutical fentanyl in lethal injection protocols, does not present any direct conflicts of interest for the sponsor, Janince Bowling. As a former educator and businesswoman, her documented personal financial interests do not align with the pharmaceutical or drug safety industries that would be impacted by this legislation. Furthermore, her role as a Tennessee State Senator does not indicate any financial stake in the outcomes of this bill. Therefore, there are no evident personal financial gains that could arise from the passage of this legislation.

Sponsor's Personal Financial Interests

Unlike federal analysis based on campaign donations, state analysis examines legislators' personal financial interests — their jobs, businesses, and investments.

Type Description Industry Source
Occupation Former educator and businesswoman AI-researched
Employer Tennessee State Senator TN Legislature bio

Items marked "AI-researched" are generated from public sources but have not been independently verified. Verified data is sourced from official legislature websites and disclosure filings.

TheBillRoom is free and independent. No ads, no subscriptions, no political funding. If this analysis was useful, reader support keeps it running.
Support Us

About This Analysis

This summary was generated using AI from the bill's official text and metadata. Data sourced from LegiScan and the Tennessee General Assembly. Conflict analysis examines the sponsor's personal financial interests for potential overlaps with the bill's subject matter.